Recent Updates — LNTH
The Federal Trade Commission issued a Second Request for additional information and documentary materials regarding the proposed merger between Lantheus Holdings, Inc. and Curium US Holdings LLC. This regulatory action extends the Hart-Scott-Rodino Act waiting period until 30 days after both parties substantially comply with the request. The company expects to respond promptly and continue cooperating with the FTC. Completion of the transaction remains subject to the expiration or termination of this waiting period, with the parties still targeting consummation in the first half of 2027. Lantheus Holdings develops and commercializes diagnostic imaging agents for nuclear medicine.
At a special meeting held on October 14, 2026, Lantheus Holdings, Inc. shareholders approved the adoption of an Agreement and Plan of Merger dated August 3, 2026, with Curium US Holdings LLC. The transaction involves the merger of Coco Merger Sub Inc., a wholly owned subsidiary of Parent, into Lantheus, making Lantheus a wholly owned subsidiary of Curium. The merger proposal received approximately 97% approval, while shareholders also approved an advisory vote on executive compensation related to the deal. This filing reports the results of the shareholder vote required for the transaction's completion. Lantheus Holdings develops and commercializes diagnostic imaging agents.
Lantheus Holdings filed an 8-K to disclose supplemental information regarding its proposed merger with Curium US Holdings LLC following the filing of three stockholder complaints alleging omissions in the definitive proxy statement concerning financial projections and Morgan Stanley's fairness opinion. To address these claims without admitting liability, Lantheus disclosed updated details from Morgan Stanley’s valuation analysis as of June 30, 2026. The discounted cash flow analysis yielded an implied value per share of $88.10 to $118.60, while the publicly traded companies analysis resulted in a range of $63.85 to $84.20. These valuations were based on 68.2 million fully diluted shares, $593 million in cash, and $575 million in convertible debt. The company also disclosed that Morgan Stanley held between 2% and 3% of Lantheus common stock and received fees of $5 million to $10 million from both Lantheus and CapVest affiliates over the prior two years. Lantheus Holdings, Inc. operates in the medical imaging industry, developing and commercializing radiopharmaceuticals for oncology and neurology.
Lantheus Holdings, Inc. voluntarily withdrew its pre-merger notification under the Hart-Scott-Rodino Act to allow additional time for Federal Trade Commission review of its proposed acquisition by Curium US Holdings LLC. The company resubmitted the notification on September 21, 2026, commencing a new 30-day waiting period that expires on October 21, 2026. Lantheus and Parent continue to expect consummation of the merger in the first half of 2027, subject to regulatory approvals and stockholder adoption. The company operates in the radiopharmaceutical industry, developing and commercializing diagnostic imaging agents.
Lantheus Holdings reported second quarter 2026 financial results with worldwide revenue of $388.2 million, a 2.7% increase from the prior year period. GAAP fully diluted earnings per share were $1.11, while adjusted fully diluted EPS was $1.55. The company suspended its full-year 2026 financial guidance and will not host an earnings conference call due to pending M&A activity. On August 3, 2026, Lantheus entered into a definitive agreement to merge with Curium in an all-cash transaction valued at up to approximately $8.0 billion. Under the deal, shareholders will receive $102.50 per share plus Contingent Value Rights providing for up to $12.00 per share based on commercial milestones through 2030. The combined entity aims to create a radiopharmaceutical company spanning diagnostics and therapeutics across more than 70 countries. Lantheus is a leading radiopharmaceutical-focused company delivering diagnostic and therapeutic solutions.
Lantheus Holdings, Inc. entered into a definitive Agreement and Plan of Merger with Curium US Holdings LLC on August 3, 2026, pursuant to which Lantheus will be acquired in an all-cash transaction valued at $102.50 per share. The consideration includes one contractual contingent value right (CVR) per share, entitling holders to receive up to $12.00 in cash upon the achievement of specific commercial milestones for the Global Prostate Cancer Diagnostics, Global Neurology Diagnostics, and Global DEFINITY franchises. The merger is not subject to any financing condition, with Parent having secured equity and debt commitments. Closing is conditioned on stockholder approval, regulatory clearances including Hart-Scott-Rodino expiration, and the absence of a Material Adverse Effect. If terminated under specific circumstances, Curium must pay Lantheus a $385 million termination fee or a $100 million regulatory fee. The company operates in the medical diagnostics industry, specializing in radiopharmaceuticals for oncology and neurology.